Experience with Bevacizumab in Neuroendocrine Tumors

#1094

Introduction: Bevacizumab has shown promising activity in neuroendocrine tumors (NET) in combination with a multitude of other substances.

Aim(s): To analyze the efficacy and toxicity of bevacizumab-containing protocols in NET.

Materials and methods: We performed a retrospective analysis of all patients treated with bevacizumab-containing protocols for metastatic NET who presented at our center between August 2008 and December 2014.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Apostolidis L

Authors: Apostolidis L, Jäger D, Winkler E,

Keywords: neuroendocrine tumor, targeted therapy, bevacizumab, anti-angiogenesis,

To read the full abstract, please log into your ENETS Member account.